Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.

BMC cancer - 27 Feb 2018

Brogden Kim A, Parashar Deepak, Hallier Andrea R, Braun Terry, Qian Fang, Rizvi Naiyer A, Bossler Aaron D, Milhem Mohammed M, Chan Timothy A, Abbasi Taher, Vali Shireen

Abstract excerpt

BACKGROUND: Programmed Death Ligand 1 (PD-L1) is a co-stimulatory and immune checkpoint protein. PD-L1 expression in non-small cell lung cancers (NSCLC) is a hallmark of adaptive resistance and its expression is often used to predict the outcome of Programmed Death 1 (PD-1) and PD-L1 immunotherapy treatments. However, clinical benefits do not occur in all patients and new approaches are needed to assist in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Carcinoma, Non-Small-Cell Lung

Share to Chemokines

Share to Computer Simulation

Share to Immunotherapy

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 29486723
DOI: 10.1186/s12885-018-4134-y
PMCID: PMC5897943

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.PMID 29486723Read ↗

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.Semantic proximity Read ↗

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung CancerSemantic proximity Read ↗

Shedding light on the molecular determinants of response to anti-PD-1 therapy.Semantic proximity Read ↗

Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.Semantic proximity Read ↗

Blood-based Genomic and Cellular Determinants of Response to Neoadjuvant PD-1 Blockade in Patients with Non-Small-Cell Lung CancerSemantic proximity Read ↗

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung CancerSemantic proximity Read ↗

Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.Semantic proximity Read ↗

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Semantic proximity Read ↗

Mutation mapping of PD-L1 expression in advanced non-small cell lung cancer: A real-world retrospective cohort studySemantic proximity Read ↗

Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung CancerSemantic proximity Read ↗

Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity Read ↗

Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.